# Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

> **NCT01514864** · PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 19 (actual)

## Conditions studied

- Carcinoma, Non-small Cell Lung

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01514864
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05-31
- **Primary completion:** 2014-07-23
- **Final completion:** 2014-07-23
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Lack of efficacy and slow accrual
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01514864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01514864, "Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01514864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*